Elafibranor 80mg + Elafibranor 120mg
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non Alcoholic Steatohepatitis
Conditions
Non Alcoholic Steatohepatitis
Trial Timeline
Jun 25, 2019 → Jun 16, 2020
NCT ID
NCT03883607About Elafibranor 80mg + Elafibranor 120mg
Elafibranor 80mg + Elafibranor 120mg is a phase 2 stage product being developed by Genfit for Non Alcoholic Steatohepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03883607. Target conditions include Non Alcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03883607 | Phase 2 | Terminated |
Competing Products
20 competing products in Non Alcoholic Steatohepatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| AZD9550 + AZD9550 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZD2693 | AstraZeneca | Phase 1 | 33 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD4831 | AstraZeneca | Phase 2 | 52 |
| AZD2693 | AstraZeneca | Phase 2 | 52 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| cotadutide solution for injection | AstraZeneca | Phase 1 | 33 |
| Cotadutide + Cotadutide-placebo + Moxifloxacin + Moxifloxacin-placebo | AstraZeneca | Phase 1 | 33 |